Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of ZGN-1061 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus to Evaluate Glycemic Control, Safety, and Tolerability Over 12 Weeks

Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of ZGN-1061 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus to Evaluate Glycemic Control, Safety, and Tolerability Over 12 Weeks

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs ZGN 1061 (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Zafgen
  • Most Recent Events

    • 12 Sep 2017 According to a Zafgen media release, interim data is expected in first half of 2018.
    • 12 Sep 2017 According to a Zafgen media release, first patient has been dosed.
    • 12 Sep 2017 Status changed from not yet recruiting to recruiting, according to a Zafgen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top